1
Home
Companies

Cyteir Therapeutics

Cyteir Therapeutics
Leadership team

Mr. Joseph S. Zakrzewski (Independent Investor & Independent Chairman)

Dr. Markus F. Renschler M.D. (Pres, CEO & Director)

Mr. Timothy Romberger (Independent Director)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Cambridge, Massachusetts, United States
Established
2012
Company Registration
SEC CIK number: 0001662244
Traded as
NASDAQ:CYT
Social Media
URL
https://cyteir.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
History

Cyteir Therapeutics was founded by Greg Verdine in 2014. We have a team of scientists, technologists and clinicians pioneering a new generation of therapeutic cancer treatments. With our unique combination of next-generation technologies and pre-clinical expertise, we have become a leader in the research and development of efficacious and safe cancer treatments.

Mission
Our mission is to develop transformative and life-saving treatments for patients with cancer through innovative precision oncology approaches.
Vision
Our vision is to become the premier precision oncology company for our partners, patients and shareholders.
Key Team

Dr. Paul Secrist Ph.D. (Chief Scientific Officer)

Mr. Andrew W. Gengos (Chief Bus. Officer & Sec.)

Mr. David G. Gaiero (VP of Fin.)

Dr. Kevin Mills Ph.D. (Co-Founder)

Ms. Lisa A. Hayes (VP of Investor Relations & Corp. Communications)

Ms. Gale Cohen (VP of HR)

Mr. Adam M. Veness Esq. (Gen. Counsel)

Recognition and Awards
Cyteir Therapeutics has been recognized with numerous awards, including “Best Oncology Company” from MassBio’s 2015 Boston Life Science Awards and “Most Innovative Company of the Year” from ASME’s 2016 Innovation Showcase.
References

https://in.investing.com/equities/cyteir-therapeutics

https://finance.yahoo.com/quote/CYT/profile?p=CYT

https://www.crunchbase.com/organization/cyteir-therapeutics

https://cyteir.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Cyteir Therapeutics
Leadership team

Mr. Joseph S. Zakrzewski (Independent Investor & Independent Chairman)

Dr. Markus F. Renschler M.D. (Pres, CEO & Director)

Mr. Timothy Romberger (Independent Director)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Cambridge, Massachusetts, United States
Established
2012
Company Registration
SEC CIK number: 0001662244
Traded as
NASDAQ:CYT
Social Media
URL
https://cyteir.com